<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03278470</url>
  </required_header>
  <id_info>
    <org_study_id>HL-237-101</org_study_id>
    <nct_id>NCT03278470</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject</brief_title>
  <official_title>A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximum Tolerable Dose After Single Oral Dose of HL237 in Healthy Male Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic
      structure of biguanide in metformin, an existing diabetes drug.

      The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3
      inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and
      activating Treg cells.

      Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune
      diseases such as rheumatoid arthritis.

      This is the first clinical trial to be conducted for the development of HL237 and this
      clinical trial is for determining the maximum oral dose of HL237 and assessing safety,
      tolerability, and pharmacokinetic characteristics for each dose group.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">March 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>3days after administration</time_frame>
    <description>maximum serum concentration after the drug has been administrated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>3days after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>half life [t1/2]</measure>
    <time_frame>3days after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>14days after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>HL237 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HL237 1600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>take oral tablet once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL237</intervention_name>
    <description>Experimental</description>
    <arm_group_label>HL237 50mg</arm_group_label>
    <arm_group_label>HL237 100mg</arm_group_label>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_label>HL237 800mg</arm_group_label>
    <arm_group_label>HL237 1200mg</arm_group_label>
    <arm_group_label>HL237 1600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo with same properties except for active ingredient</description>
    <arm_group_label>HL237 50mg</arm_group_label>
    <arm_group_label>HL237 100mg</arm_group_label>
    <arm_group_label>HL237 200mg</arm_group_label>
    <arm_group_label>HL237 400mg</arm_group_label>
    <arm_group_label>HL237 800mg</arm_group_label>
    <arm_group_label>HL237 1200mg</arm_group_label>
    <arm_group_label>HL237 1600mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy adult male aged 20 years or older and 45 years old at the time of the
             screening test

          -  Those who weigh more than 55kg but weigh less than Â± 20% of ideal body weight

          -  Proper contraception during the clinical trial period

          -  After hearing the detailed explanation of the clinical trial, those who decide to
             participate voluntarily and write agreement

        Exclusion Criteria:

          -  Clinically significant, a person with a history of neurological, psychiatric,
             malignant, cardiovascular, respiratory, kidney, endocrine, hematologic, digestive or
             central disease

          -  a person with a history of gastrointestinal disorders that may affect the absorption
             of pharmaceuticals for clinical trials (Crohn's disease, ulcers, etc.) or
             gastrointestinal surgery (except for simple cecal surgery or hernia surgery)

          -  a person with a history of hypersensitivity or clinically significant hypersensitivity
             to the clinical trial drug or additives

          -  a person judged to be inappropriate for the subject by health screening (history of
             disease, physical examination, vital signs, electrocardiogram, laboratory test, etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The catholic university of korea seoul ST. mary's hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>September 10, 2017</last_update_submitted>
  <last_update_submitted_qc>September 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

